AcuCort’s CEO Jonas Jönmark to take part in live broadcast on rights issue and US expansion

AcuCort CEO Jonas Jönmark is scheduled to discuss the company’s rights issue, US FDA process for Zeqmelit® and international expansion in a live interview on Tuesday 6 October at 12:00 CET. Topics include use of rights-issue proceeds, preparations for a planned US New Drug Application, a potential US launch and upcoming milestones; the article gives no financial amounts or new regulatory outcome.

Analysis

This is a communications event, not evidence of a change in regulatory or commercial probability. For ACUC, the key distinction is whether the rights issue finances a defined path to an NDA or merely moves the next funding decision out. Capital that supports US regulatory work may reduce near-term financing risk, but launch preparation could consume proceeds before approval or demand is demonstrated; an NDA plan is not FDA acceptance or approval. The interview’s value is therefore in new, checkable detail: net proceeds, runway assumptions, NDA submission timing and readiness, and whether US commercialization depends on a partner.

Near term, expect event-driven volatility rather than a durable re-rating absent specifics. Over 1–3 months, milestones and any revised cash-runway disclosure matter more than management’s stated ambition. Over 6–18 months, regulatory execution and the cost and route of US commercialization determine whether dilution buys meaningful value or precedes another capital raise. A stated timeline slipping, a materially shorter runway than implied, or new financing needs would falsify the constructive funding interpretation; concrete, funded milestones would weaken the financing-risk case.

Key Decisions for Investors

• No directional trade solely on the interview notice. Treat ACUC as a watch item until the rights-issue terms and proceeds, including any underwriting or subscription support, are verifiable.
• After the interview, compare disclosed net proceeds and cash runway with the stated NDA workplan. If funding does not credibly cover the next regulatory milestone, avoid treating the raise as having resolved financing risk.
• Do not price the planned NDA or future US launch as achieved catalysts. Look for specific submission timing, evidence of FDA-process readiness, and a clear commercialization or partnering plan before adding exposure.
• For an existing position, use milestone slippage or a shorter-than-expected runway as thesis-break signals; a funded, dated regulatory path with no near-term financing gap would be the key evidence against the dilution-risk view.